Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Labcorp (LH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LH is expected to perform strongly in both of its segments and will also likely advance in its strategic priorities.
LH is well-placed for long-term success in Cell & Gene Therapy, expanding into the consumer market and international growth through the specialty testing and biopharma business.
Labcorp's expanding testing solutions in high-growth areas, partnerships and focus on operational efficiency instill optimism.
Labcorp expands the molecular bioanalytical laboratory in Greenfield, IN.
LH completes the acquisition of BioReference Health, a wholly-owned subsidiary of OPKO Health. The acquisition includes BioReference Health's laboratory testing businesses.
LH is well-placed for long-term success in Cell & Gene Therapy, expanding into the consumer market and international growth through the specialty testing and biopharma business.
Labcorp has reached an agreement to purchase select outreach laboratory services from Ballad Health.
Diagnostics firm Labcorp said it is processing approximately 500 mpox tests a month but have the capacity to process approximately 25,000 per month.
Labcorp's (LH) slew of partnerships and acquisitions and robust efforts in high-growth areas bode well.
Labcorp's (LH) Biopharma Laboratory Services business is benefiting from collaborations with leading pharmaceutical and biotechnology companies.